GlassScriptPhysician profile
Challie A Minton
NPI 1831392174
$16,616.36
in general payments reported to CMS, 2019-2025
55 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,949 · 2020: $2,455 · 2021: $2,979 · 2022: $2,578 · 2023: $2,246 · 2024: $2,334 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,576 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,576.05 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,663.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,830.32 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,496.41 | 2019-2025 | |
| Amgen INC. | $1,130.56 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $970.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $693.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $660.69 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $590.66 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Mylan Specialty L.P. | $444.35 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.51 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $422.34 | 2019-2023 | |
| Indivior INC. | $370.63 | 2023-2025 | Sublocade |
| Amarin Pharma, INC. | $350.33 | 2020-2021 | |
| Preventric Diagnostics, INC. | $342.07 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $338.26 | 2020-2025 | Rexulti |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$97,210.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Challie Minton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.